$RAPH Balance Sheet | Understand Stock

$RAPH

$1.40 +$0.00 (0.0%) Close

Financial Statements

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets:
Cash and cash equivalents
Other current assets
Total current assets
Fixed assets, net
Total assets
Current liabilities:
Accounts payable
Short-term credit from a related party
Related party
Total short-term credit from a related party
Other account payables and accrued expenses
Payable to related party
Related party
Total payable to related party
Total current liabilities
Stockholders’ equity (deficit):
Common stock, $0.01 par value: Authorized: 50,000,000 shares at June 30, 2026, and 21,020,560 shares at December 31, 2025; Issued and outstanding: 20,176,418 at June 30, 2026 and at December 31, 2025.
Receivable on account of shares
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)

Comments